Advances and Trends in Omics Technology Development

Xiaofeng Dai, Li ShenFrontiers in Medicine 2022 · DOI

Abstract

The human history has witnessed the rapid development of technologies such as high-throughput sequencing and mass spectrometry that led to the concept of "omics" and methodological advancement in systematically interrogating a cellular system. Yet, the ever-growing types of molecules and regulatory mechanisms being discovered have been persistently transforming our understandings on the cellular machinery. This renders cell omics seemingly, like the universe, expand with no limit and our goal toward the complete harness of the cellular system merely impossible. Therefore, it is imperative to review what has been done and is being done to predict what can be done toward the translation of omics information to disease control with minimal cell perturbation. With a focus on the "four big omics," i.e., genomics, transcriptomics, proteomics, metabolomics, we delineate hierarchies of these omics together with their epiomics and interactomics, and review technologies developed for interrogation. We predict, among others, redoxomics as an emerging omics layer that views cell decision toward the physiological or pathological state as a fine-tuned redox balance.

Introduction: The Expanding Omics Universe

Biological systems are inherently dynamic, multi-layered, and profoundly complex. While the "Central Dogma" of molecular biology (DNA → RNA → Protein) established a foundational linear flow of information, modern research has revealed that every layer is subject to intricate "epi-modifications" and extensive cross-talk, known as interactomics. The continuous discovery of new molecular species and regulatory mechanisms has created a "data deluge," where the primary challenge has shifted from data generation to the meaningful integration of multi-layered information to understand disease states.

This paper addresses the perceived impossibility of a "complete harness" of cellular machinery by organizing the disparate technologies into a coherent hierarchy. By categorizing the field into technology-based and knowledge-based domains, we can better forecast which emerging trends—such as redoxomics—will bridge the gap between laboratory discovery and clinical practice.

A Conceptual Framework for Omics

To navigate the omics landscape, we establish a framework that classifies the field into three primary layers:

  1. Technology-based Omics: This encompasses the "Big Four" (Genomics, Transcriptomics, Proteomics, and Metabolomics) along with their respective Epi-omics (e.g., the epigenome, epitranscriptome, and epiproteome).
  2. Interactomics: This crucial layer maps the physical and functional interactions between different molecular classes, such as DNA-protein or protein-metabolite interactions.
  3. Knowledge-based Omics: These represent domain-specific integrations, such as Immunomics or Microbiomics, which synthesize multiple data types to characterize specific biological systems.
The hierarchy and classification of the omics landscape, distinguishing between technology-based and knowledge-based domains.

Technological Evolution of the "Big Four"

The rapid advancement of high-throughput technologies has been the engine of the omics revolution. While Next-Generation Sequencing (NGS) remains the workhorse for throughput and cost-efficiency, Third-Generation Sequencing (TGS) platforms like PacBio and Oxford Nanopore (ONT) are becoming essential for capturing structural variants and long-range genomic information that short-read methods often miss.

In the realm of transcriptomics, single-cell RNA sequencing (scRNA-seq) has transitioned from a specialized tool to a primary method for deconstructing cellular heterogeneity. This allows researchers to identify signals within specific cell populations that were previously obscured in bulk "average" samples.

Comparison of methodologies, advantages, and disadvantages for genomics and transcriptomics technologies.

Mass spectrometry (MS) continues to dominate proteomics and metabolomics. However, these fields face unique challenges compared to sequencing-based omics, including lower reproducibility and higher false-negative rates due to the complexity of sample processing and the lack of standardized computational pipelines.

Emerging Frontiers and the Role of Redoxomics

The future of omics is moving beyond static snapshots toward spatio-temporal resolution. Spatial Omics preserves the physical context of cells within tissues, while "Info-omics" incorporates the dimensions of time and treatment duration.

Perhaps the most significant prediction is the emergence of redoxomics. We propose that a cell's fundamental decision to maintain homeostasis or progress toward a pathological state (such as malignancy) is governed by a fine-tuned redox balance. By measuring oxidative cysteine modifications at an omics scale, researchers may find a more direct path to understanding and diagnosing disease states.

Challenges to Clinical Translation

Despite these advances, several bottlenecks hinder the translation of omics data into clinical utility:

  • Sample Scarcity: High-quality multi-omics analysis often requires significant sample volumes, which is problematic for rare diseases or small clinical biopsies.
  • The "Dry Lab" Bottleneck: Technological progress in "wet lab" instrumentation is currently outstripping our computational ability to integrate heterogeneous data. Future efforts must prioritize machine learning algorithms capable of handling multi-layer complexity.
  • Clinical Complexity: A significant gap remains between identifying a molecular signature and predicting a patient's treatment response. The next decade must focus on "minimal cell perturbation"—leveraging omics data to control disease without disrupting healthy cellular functions.

Summary updated

Abstract

The human history has witnessed the rapid development of technologies such as high-throughput sequencing and mass spectrometry that led to the concept of "omics" and methodological advancement in systematically interrogating a cellular system. Yet, the ever-growing types of molecules and regulatory mechanisms being discovered have been persistently transforming our understandings on the cellular machinery. This renders cell omics seemingly, like the universe, expand with no limit and our goal toward the complete harness of the cellular system merely impossible. Therefore, it is imperative to review what has been done and is being done to predict what can be done toward the translation of omics information to disease control with minimal cell perturbation. With a focus on the "four big omics," i.e., genomics, transcriptomics, proteomics, metabolomics, we delineate hierarchies of these omics together with their epiomics and interactomics, and review technologies developed for interrogation. We predict, among others, redoxomics as an emerging omics layer that views cell decision toward the physiological or pathological state as a fine-tuned redox balance.
BibTeX
@inproceedings{dai2022advances,
  author = {Xiaofeng Dai and Li Shen},
  title = {{Advances and Trends in Omics Technology Development}},
  booktitle = {Frontiers in Medicine},
  year = {2022},
  doi = {10.3389/fmed.2022.911861},
}
Figure